Mesa Labs director John Sullivan sells $800,090 in stock
Mesa Laboratories director John Sullivan sold 7,093 shares of common stock for $800,090, with each share priced at $112.80. The transaction occurred on August 13, 2026, and the shares were sold to Mesa’s President and CEO, Siddhartha Kadia. Following the sale, Sullivan directly holds 17,834 shares, with an additional 45,110 shares held indirectly through a family trust.
Mesa Laboratories (NASDAQ: MLAB) director now holds 6,973 shares
Mesa Laboratories director Shannon Hall acquired 2,784 shares of common stock through the vesting and settlement of Restricted Stock Units (RSUs) on August 15, 2026. This transaction increased Hall's direct common stock holding to 6,973 shares, while the derivative RSU position was reduced to zero. The Form 4 filing indicates a neutral impact and sentiment regarding this insider trading activity.
Mesa Labs director John Sullivan sells $800,090 in stock By Investing.com
John Sullivan, a director at Mesa Laboratories Inc., sold 7,093 shares of common stock for $800,090 at $112.80 per share on August 13, 2026. The shares were purchased by Mesa's President and CEO, Siddhartha Kadia, while MLAB stock is trading near its 52-week high and shows a 55% return over the past year. Following the transaction, Sullivan directly holds 17,834 shares, with an additional 45,110 shares held indirectly by a family trust.
Mesa Labs (NASDAQ: MLAB) director settles 3,810 RSUs into stock
Mesa Labs director Shiraz Shabanali Ladiwala reported the settlement of 3,810 Restricted Stock Units (RSUs) into common stock on August 15, 2026. These RSUs converted to 3,810 shares of common stock at an exercise price of $0.00 per share. Following this transaction, Ladiwala directly owns 12,333 shares of MLAB common stock.
Mesa Laboratories (NASDAQ: MLAB) director adds 2,784 shares via RSU vesting
Mesa Laboratories director Mark Christopher Capone acquired 2,784 shares of common stock through the vesting and exercise of Restricted Stock Units (RSUs) on August 15, 2026. This transaction increased his direct holdings of Mesa Laboratories common stock to 6,213 shares, while his derivative RSU position was reduced to zero. The RSUs vested at a transaction price of $0.00 per share, indicating no monetary cost for the acquisition.
Mesa Labs (NASDAQ: MLAB) director adds 2,784 shares from RSUs
Mesa Laboratories director Jennifer Sadie Alltoft acquired 2,784 shares of common stock through the vesting and settlement of Restricted Stock Units (RSUs) on August 15, 2026. This transaction resulted in Alltoft directly holding 7,662 shares of MLAB common stock, with no remaining RSUs from this specific award. The acquisition was a non-cash event at a stated price of $0.00 per share and was not executed under a Rule 10b5-1 trading plan.
Mesa Laboratories (NASDAQ: MLAB) director adds stock via RSU vesting
Mesa Laboratories director R. Tony Tripeny recently acquired 2,784 shares of common stock through the vesting of Restricted Stock Units (RSUs) on August 15, 2026. This transaction increased his direct holdings to 9,082 shares, and the RSU derivative position was reduced to zero. The Form 4 filing indicates this was a routine equity award settlement, not an open-market purchase or sale.
Diamond Hill Capital Management LLC Investment Advisor Makes New Investment in Mesa Laboratories, Inc. $MLAB
Diamond Hill Capital Management LLC initiated a new position in Mesa Laboratories (NASDAQ:MLAB) by purchasing 155,771 shares valued at approximately $15.5 million, representing 2.78% of the company. Institutional investors now own 90.6% of MLAB. Analysts maintain a "Hold" rating with an average target price of $110, following recent adjustments from Wells Fargo and Wall Street Zen.
Siddhartha Kadia Buys 7,093 Shares of Mesa Laboratories (NASDAQ:MLAB) Stock
Mesa Laboratories CEO Siddhartha Kadia recently purchased 7,093 shares of the company's stock for approximately $800,090. Following this transaction, his total ownership increased to 7,093 shares. The company's shares rose 2.0% to $108.19, and it reported quarterly revenue of $60.14 million and earnings of $2.68 per share, along with a quarterly dividend of $0.16 per share.
R Tony Tripeny Acquires 900 Shares of Mesa Laboratories (NASDAQ:MLAB) Stock
Director R. Tony Tripeny recently purchased 900 shares of Mesa Laboratories (NASDAQ:MLAB) stock for over $102,000, increasing his direct ownership by 16.67%. The company reported quarterly revenue of $60.14 million and earnings of $2.68 per share, with its stock trading up 2.0% to $108.19. Analysts currently maintain a "Hold" rating for MLAB with a consensus target price of $110.00.
Mesa Labs director John Sullivan sells $800,090 in stock
Mesa Laboratories director John Sullivan sold 7,093 shares of common stock for $800,090 to CEO Siddhartha Kadia on August 13, 2026. Following the transaction, Sullivan directly holds 17,834 shares, with an additional 45,110 shares held indirectly by a family trust. The sale occurred as MLAB stock trades near its 52-week high after a 55% return over the past year.
Mesa Laboratories CEO Kadia buys $800,090 in stock
Mesa Laboratories Inc.'s CEO, Siddhartha Kadia, recently purchased 7,093 shares of company stock for $800,090. This transaction occurred on August 13, 2026, at $112.80 per share, close to its 52-week high. The acquisition was made indirectly through a trust from Mesa’s Board Chair, John Sullivan, following the company's fiscal first-quarter revenue miss.
Mesa Laboratories (NASDAQ: MLAB) director sells shares to CEO
Mesa Laboratories director John James Sullivan sold 7,093 shares of common stock to President and CEO Siddhartha Kadia on August 13, 2026, for $112.80 per share in a private transaction. After the sale, Sullivan directly holds 17,834 shares and indirectly holds 45,110 shares through the Sullivan Family Trust. The transaction was not conducted under a Rule 10b5-1 trading plan.
Mesa Laboratories (NASDAQ: MLAB) director lifts stake to 6,298 shares
Mesa Laboratories Inc. director R. Tony Tripeny recently increased his direct stake in the company by purchasing 900 shares of common stock at $113.69 per share on August 13, 2026. This transaction raised his total direct holdings to 6,298 shares. The Form 4 filing indicates this was a non-derivative, open-market purchase and not made under a Rule 10b5-1 plan.
Wasatch Advisors LP Increases Position in Mesa Laboratories, Inc. $MLAB
Wasatch Advisors LP significantly increased its stake in Mesa Laboratories, Inc. (NASDAQ:MLAB) by 125.8% in the second quarter, now owning 115,668 shares valued at $11.5 million. This comes as other institutional investors also adjusted their positions in the medical instruments supplier. Despite an overall "Hold" rating from analysts with an average price target of $94, the stock recently opened at $112.80, while insiders have sold shares to cover tax obligations.
Mesa Laboratories (MLAB) Stock Jumps As Margin Gains Meet Backlog Doubts
Mesa Laboratories' stock jumped 9.5% after its Q1 2027 earnings, with investors focusing on improved profitability despite modest revenue growth. Gross margins increased, and cash generation was solid, but net income and EPS declined year-on-year. The company faces risks from backlog issues and customer frustration in its largest segment, raising questions about whether the current high P/E is justified.
Mesa Laboratories, Inc. Q1 2027 Earnings Call Summary
Mesa Laboratories, Inc. is pivoting its strategy from aggressive M&A to internal execution and "self-help" to address recent underperformance, which management attributes to fixable operational issues rather than structural demand shifts. The company is focusing on strengthening its balance sheet, re-prioritizing R&D for its next-generation Gyrolab platform, and implementing cultural changes to improve efficiency and customer loyalty, particularly within its Sterilization and Disinfection Controls (SDC) and Biopharmaceutical Development (BPD) segments. Fiscal 2027 guidance is deferred, and management is working to resolve an increased SDC backlog and rebuild the BPD commercial engine.
Mesa Labs Posts Margin Surge, Pays Down $8.7 Million in Debt as New CEO Tackles Delivery Delays
Mesa Laboratories reported a 1% increase in Q1 revenue to $60.1 million, with adjusted operating income surging nearly 20% and gross margin expanding to 64.9% due to cost controls. The company generated $14.7 million in operating cash flow and repaid $8.7 million in debt, reducing its net leverage. However, its largest division, Sterilization and Disinfection Control, saw organic revenue decline due to delivery issues, which new CEO Siddhartha Kadia is prioritizing to fix.
Press Release: Mesa Labs Announces First Quarter Results
This is a press release from Mesa Labs announcing their first-quarter results. The document provided was empty, so no further summary can be generated.
Mesa Laboratories Inc (MLAB) (Q1 2027) Earnings Call Highlights: Margin Expansion and Debt ...
Mesa Laboratories Inc. (MLAB) reported its Q1 2027 earnings, showing a 1% increase in total revenue to $60.1 million and a significant 16.5% rise in adjusted operating income. The company achieved margin expansion and reduced its net leverage ratio to 1.85x by repaying $8.7 million in debt. While some segments like BPD and Calibration Solutions saw organic growth, the SDC segment experienced a revenue decline due to delivery issues, and GAAP net income decreased by 40.3% because of currency swings.
Mesa Laboratories Inc /Co/ 2026: Revenue $60.14M, EPS $0.49— 10-Q Summary
Mesa Laboratories Inc /Co/ reported its 2026 quarterly results with revenue slightly up to $60.14M from $59.54M the previous year. However, net income decreased by 40.3% to $2.83M, and diluted EPS fell by 42.4% to $0.49. The company highlighted revenue growth in Calibration Solutions and Biopharma Development, improved gross margin, and increased operating income due to cost containment.
Mesa Laboratories (MLAB) lifts Q1 margins and cash flow while net income falls
Mesa Laboratories (MLAB) reported Q1 FY2027 revenue of $60,138, a 1.0% increase year-over-year, with gross profit rising to $39,012 due to improved gross margins. Operating income more than doubled to $7,031, and operating cash flow strengthened significantly to $14,736, leading to a net debt reduction. However, net income fell to $2,830 from $4,742 in the prior year, primarily due to the non-recurrence of a foreign currency gain.
Mesa Labs Announces First Quarter Results
Mesa Laboratories, Inc. (NASDAQ:MLAB) announced its first fiscal quarter (1Q27) results, reporting a 1.0% increase in revenues to $60,138 thousand. Non-GAAP adjusted operating income (AOI) excluding unusual items rose 19.5%, reaching 25.6% of revenues. The company also reduced its Total Net Leverage Ratio to 1.85, exceeding its target, and highlighted positive core organic growth driven by its Biopharmaceutical Development and Calibration Solutions divisions.
Mesa Labs Announces First Quarter Results
Mesa Laboratories, Inc. (NASDAQ:MLAB) announced its first fiscal quarter results for 1Q27, ending June 30, 2026. The company reported a 1.0% increase in revenues and a 129% increase in operating income, driven by growth in its Calibration Solutions and Biopharmaceutical Development divisions. Mesa Labs also reduced its total net leverage ratio to 1.85, exceeding its target.
Mesa Labs Announces First Quarter Results
Mesa Laboratories, Inc. announced its first fiscal quarter results, showing a 1.0% increase in revenues and a 129% increase in operating income. The company reported positive core organic growth driven by its Calibration Solutions and Biopharmaceutical Development divisions, with a significant reduction in its Total Net Leverage Ratio to 1.85. Mesa's new CEO, Siddhartha Kadia, emphasized disciplined execution and profitable growth across its four divisions.
Renaissance Technologies LLC Has $2.79 Million Holdings in Mesa Laboratories, Inc. $MLAB
Renaissance Technologies LLC significantly increased its stake in Mesa Laboratories (MLAB) by 802.9% in Q1, now holding 31,600 shares valued at $2.79 million. Despite institutional ownership reaching 90.6%, the company missed Q1 analyst estimates for revenue and EPS. Analysts maintain a "Reduce" rating for MLAB, and insiders have sold shares worth approximately $770,000 recently.
Mesa Laboratories, Inc. expected to post earnings of 3 cents a share - Earnings Preview
Mesa Laboratories, Inc. (MLAB) is anticipated to report earnings of 3 cents per share. This earnings preview is based on information from Refinitiv and was published on TradingView News.
Mesa Laboratories Inc (MLAB) Earnings Forecast: Future EPS & Revenue Growth Estimates
Mesa Laboratories Inc (MLAB) has an earnings forecast score of 7.33, ranking 141st in its industry, with an average price target of $95.00 from three analysts. Analysts generally recommend a "Buy" for MLAB, anticipating next quarter's revenue at $60.87 million and EPS at $0.03.
Janus Henderson Group PLC Cuts Holdings in Mesa Laboratories, Inc. $MLAB
Janus Henderson Group PLC significantly reduced its stake in Mesa Laboratories, Inc. by 40.5% in the first quarter of 2026, selling over 47,000 shares. Despite other institutional investors increasing their holdings, company insiders sold a substantial number of shares. Mesa Laboratories also missed its quarterly earnings and revenue estimates, maintaining a "Reduce" consensus rating from analysts with an average price target of $94.
Lazard Asset Management LLC Buys New Stake in Mesa Laboratories, Inc. $MLAB
Lazard Asset Management LLC has acquired a new stake of 20,328 shares in Mesa Laboratories (MLAB), valued at approximately $1.8 million, bringing institutional ownership to 90.6% of the company. Despite missing analyst estimates for quarterly revenue and earnings, the stock recently rose by 3.6% to $104.43, though it holds a "Reduce" consensus rating and an average analyst price target of $94. Mesa Laboratories also declared a quarterly dividend of $0.16 per share, representing a 0.6% yield.
Mesa Labs Announces First Quarter Financial Results Release Date and Inaugural Earnings Conference Call
Mesa Laboratories, Inc. (NASDAQ:MLAB) announced it will release its first fiscal quarter (1Q27) financial results, ended June 30, 2026, after market close on Monday, August 10, 2026. The company will also host its first earnings conference call on the same day at 4:30 p.m. Eastern Time, which will include a Q&A session with analysts. Details for accessing the call via toll-free number, international number, or webcast are provided in the announcement.
Mesa Labs to release Q1 2027 earnings on August 10 with a live conference call.
Mesa Labs (MSLB) will release its financial results for the first quarter of fiscal 2027, ending June 30, 2026, on August 10 after market close. The company will also host an earnings conference call at 4:30 p.m. Eastern Time on the same day to discuss the results and answer questions. Mesa Labs is a leader in life science tools and quality control solutions for the pharmaceutical, healthcare, and medical device industries.
Mesa Labs Announces First Quarter Financial Results Release Date and Inaugural Earnings Conference Call
Mesa Laboratories, Inc. (NASDAQ:MLAB) announced it will release its first fiscal quarter financial results for the period ended June 30, 2026, after market close on Monday, August 10, 2026. The company will also host its inaugural earnings conference call on the same day at 4:30 p.m. Eastern Time to discuss the results and conduct a Q&A session with analysts. Details for accessing the call via telephone or webcast are provided, along with information about a replay.
Mesa Labs to Hold Its First Earnings Call After Results Aug. 10
Mesa Labs (NASDAQ: MLAB) announced it will release its first fiscal quarter (1Q27) financial results, for the period ended June 30, 2026, after market close on Monday, August 10, 2026. The company will also host its inaugural earnings conference call on the same day at 4:30 p.m. Eastern Time to discuss these results and engage in a Q&A session with analysts. Investors can join the call via phone or webcast, and a replay will be available for 45 days on the Mesa Labs website.
Mesa Labs Announces First Quarter Financial Results Release Date and Inaugural Earnings Conference Call
Mesa Laboratories, Inc. (NASDAQ:MLAB) announced it will release its first fiscal quarter (1Q27) financial results, covering the period ended June 30, 2026, after market close on Monday, August 10, 2026. The company will also host its first earnings conference call on the same day at 4:30 p.m. Eastern Time to discuss the results and conduct a Q&A session with analysts. Details for accessing the conference call via phone or webcast have been provided.
Mesa Laboratories Inc (MLAB) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Mesa Laboratories Inc (MLAB), focusing on its support and resistance levels, various technical indicators, and moving averages. As of July 29, 2026, MLAB's price momentum score is 3.97, suggesting it is suitable for range-bound swing trading between resistance at 108.22 and support at 90.55. The analysis shows a mixed signal from indicators (1 sell, 5 neutral, 1 buy) but a strong buy signal from moving averages (5 buy, 1 sell for MA200).
Mesa Laboratories Inc (MLAB) Financial Health: Profitability & Balance Sheet Analysis
Mesa Laboratories Inc (MLAB) currently holds a financial score of 7.93, ranking 56th in the Healthcare Equipment & Supplies industry, indicating stable financial health and high operating efficiency. The company recently reported a quarterly revenue of $63.72M, marking a 2.56% year-over-year increase, and a net profit increase of 41.86% year-over-year. Despite strong operational efficiency and growth potential, several key financial metrics like cash and cash equivalents, total assets, and free cash flow have not been disclosed by the company.
Mesa Laboratories (Nasdaq:MLAB) - Stock Analysis
This report provides a comprehensive stock analysis of Mesa Laboratories (MLAB), detailing its company overview, valuation metrics, future growth potential, past performance, financial health, dividend information, management, and ownership. Key highlights include its current trading value below fair value estimates, projected earnings growth of 30.78% per year, and recent corporate news such as dividend declarations, insider transactions, and executive appointments. The analysis also covers potential risks like interest payment coverage and recent estimate revisions.
Mesa Laboratories Inc (MLAB) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article details the historical dividend payouts for Mesa Laboratories Inc (MLAB), showing a consistent interim and final cash dividend of $0.16 per share. It lists future dividend dates including record, payment, and ex-dividend dates extending into 2026. The company has distributed a total of $16.82 million in dividends over the past five years.
MLAB|Mesa Laboratories Inc|Price:97.500|Chg%:-3.450
Mesa Laboratories Inc. (MLAB) designs and manufactures life sciences tools and critical control solutions for regulated applications across pharmaceutical, healthcare, and medical device industries. The company's segments include Sterilization and Disinfection Control, Clinical Genomics, Biopharmaceutical Development, and Calibration Solutions. As of 2026Q1, 397 institutions hold MLAB shares, and the Discrete Revenues-Consumables business is its largest revenue source.
MLAB|Mesa Laboratories Inc|Price:97.500|Chg%:-3.450
Mesa Laboratories Inc (MLAB) has a strong financial outlook with high growth potential, despite a recent stock price dip. The company is considered fairly valued within the Healthcare Equipment & Supplies industry, with high institutional ownership and multiple "Buy" ratings from analysts. Its TradingKey Stock Score reflects health in fundamentals, valuation, and institutional confidence, while highlighting risks such as potential overvaluation and recent institutional selling.
MLAB|Mesa Laboratories Inc|Price:97.700|Chg%:-3.250
Mesa Laboratories Inc. (MLAB) closed at $97.50, down 3.42%, with a market cap of $538.68M. Analysts rate MLAB as "Buy" with a target price of $112.00, representing a 14.86% upside. The company shows strong fundamentals with steady revenue growth and a return to profitability, despite being considered overvalued with a high P/E of 148.35.
Mesa Laboratories Inc (MLAB) Institutional Confidence
Mesa Laboratories Inc (MLAB) has an institutional shareholding score of 10.00, placing it first in the Healthcare Equipment & Supplies industry. Institutional shareholding increased by 17.49% quarter-over-quarter, with Chuck Royce being the largest shareholder. The article details major institutional holders and their recent changes in shareholdings.
Mesa Laboratories Inc (MLAB) Valuation: PE, PB & Fair Value Analysis
Mesa Laboratories Inc (MLAB) has a current valuation score of 9.21, ranking 34th out of 200 in its industry. Its P/E ratio is 148.35, significantly below its recent high and above its recent low. Key valuation metrics like P/B, P/S, and P/CF have not yet been disclosed by the company.
Mesa Laboratories, Inc. Revenue Breakdown – NASDAQ:MLAB
Mesa Laboratories, Inc. (NASDAQ: MLAB) generated $249.13 million USD in revenue last year, with its Sterilization and Disinfection Control segment being the top performer at $101.57 million USD. The majority of the company's revenue, $116.89 million USD, came from the United States.
Mesa Laboratories Inc (MLAB) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Mesa Laboratories Inc (MLAB), detailing its current earnings forecast score of 7.33, which ranks 141 out of 200 in its industry. It includes analyst ratings, target prices, and a comparison with peer companies like Stryker Corp and Medtronic PLC. The report also addresses frequently asked questions regarding earnings surprises and the impact of earnings reports on stock volatility.
Mesa Laboratories announces annual shareholder meeting
Mesa Laboratories will hold its annual shareholder meeting on September 8, 2026, in Lakewood, Colorado. Shareholders will vote on the election of seven directors, including John Sullivan and Siddhartha Kadia, and ratify Baker Tilly as the independent auditor. An advisory vote on executive compensation will also take place.
Mesa Laboratories, Inc. $MLAB Shares Purchased by Roubaix Capital LLC
Roubaix Capital LLC increased its stake in Mesa Laboratories (MLAB) by 30.7% in Q1 2026, making it their 10th largest holding. Despite this, analyst sentiment remains cautious with a "Reduce" consensus rating and a $94 price target. Recent financial results show Mesa Laboratories missed earnings and revenue estimates, and insiders sold shares, though the company announced a quarterly dividend.
Mesa Laboratories (MLAB) Proxy Filing Summary
Mesa Laboratories (MLAB) reported strong financial performance in fiscal year 2025 with 12% revenue growth and 80% growth over five years. The company enhanced executive compensation, improved internal controls, and engaged with shareholders. Key voting matters included the election of seven director nominees, ratification of their independent auditor, and an advisory vote on executive compensation.
Mesa Laboratories (MLAB) Q2 2025 earnings summary
Mesa Laboratories (MLAB) reported a strong Q2 2025, with revenues for the six months ended September 30, 2024, increasing 11.7% to $116.0 million, and net income soaring to $6.8 million from a prior year loss. The growth was primarily fueled by the GKE acquisition and robust Biopharmaceutical Development segment. The company also improved its gross profit margin, reduced its net leverage ratio, and provided positive guidance for fiscal 2025, anticipating continued growth and improved operational efficiency.
